🇺🇸 FDA
Pipeline program

Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

CL-CA-P01

Phase 3 mab terminated

Quick answer

Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) for Stage IV Melanoma is a Phase 3 program (mab) at LISATA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LISATA THERAPEUTICS, INC.
Indication
Stage IV Melanoma
Phase
Phase 3
Modality
mab
Status
terminated

Clinical trials